

# Aaron Tan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1096950/publications.pdf>

Version: 2024-02-01

49  
papers

2,536  
citations

430754

18  
h-index

243529

44  
g-index

49  
all docs

49  
docs citations

49  
times ranked

3024  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of glioblastoma: State of the art and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 299-312.	157.7	969
2	Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2020, 11, 511-518.	0.8	275
3	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. <i>Journal of Clinical Oncology</i> , 2022, 40, 611-625.	0.8	242
4	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 2115-2120.	0.6	131
5	Molecular Pathways for Cancer Chemoprevention by Dietary Phytochemicals. <i>Nutrition and Cancer</i> , 2011, 63, 495-505.	0.9	129
6	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215.	0.9	79
7	Adapting to a Pandemic – Conducting Oncology Trials during the SARS-CoV-2 Pandemic. <i>Clinical Cancer Research</i> , 2020, 26, 3100-3103.	3.2	53
8	Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1349-1358.	0.5	48
9	The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. <i>Clinical Cancer Research</i> , 2020, 26, 5809-5813.	3.2	44
10	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
11	Potential Antioxidant, Antiinflammatory, and Proapoptotic Anticancer Activities of Kakadu Plum and Illawarra Plum Polyphenolic Fractions. <i>Nutrition and Cancer</i> , 2011, 63, 1074-1084.	0.9	38
12	Native Australian Fruit Polyphenols Inhibit Cell Viability and Induce Apoptosis in Human Cancer Cell Lines. <i>Nutrition and Cancer</i> , 2011, 63, 444-455.	0.9	37
13	Antioxidant and cytoprotective activities of native Australian fruit polyphenols. <i>Food Research International</i> , 2011, 44, 2034-2040.	2.9	32
14	Chemotherapy-induced peripheral neuropathy – patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , 2019, 27, 4771-4777.	1.0	30
15	Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1928-1934.	0.5	30
16	Native Australian fruit polyphenols inhibit COX-2 and iNOS expression in LPS-activated murine macrophages. <i>Food Research International</i> , 2011, 44, 2362-2367.	2.9	27
17	Immune Checkpoint Inhibitors in Gliomas. <i>Current Oncology Reports</i> , 2017, 19, 23.	1.8	27
18	High-Throughput Screening Platform for Anticancer Therapeutic Drug Cytotoxicity. <i>Assay and Drug Development Technologies</i> , 2008, 6, 711-722.	0.6	25

#	ARTICLE	IF	CITATIONS
19	Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2131892.	2.8	25
20	Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. International Journal of Molecular Sciences, 2020, 21, 1416.	1.8	21
21	Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. Clinical Cancer Research, 2021, 27, 5939-5950.	3.2	21
22	New drug developments in metastatic gastric cancer. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880807.	1.4	19
23	Immune Checkpoint Inhibitors for Brain Metastases. Current Oncology Reports, 2017, 19, 38.	1.8	18
24	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	3.2	18
25	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	15
26	Salting the Soil: Targeting the Microenvironment of Brain Metastases. Molecular Cancer Therapeutics, 2021, 20, 455-466.	1.9	13
27	Bystander CD4 <sup>+</sup> T cells infiltrate human tumors and are phenotypically distinct. OncoImmunology, 2022, 11, .	2.1	13
28	Characteristics and outcomes of oncology unit patients requiring admission to an Australian intensive care unit. Internal Medicine Journal, 2019, 49, 734-739.	0.5	11
29	Complementary and alternative medicine in diabetes (CALMIND) – a prospective study. Journal of Complementary and Integrative Medicine, 2015, 12, 95-99.	0.4	10
30	Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e161-e166.	0.7	10
31	Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia. BMJ Case Reports, 2018, 2018, bcr-2017-222948.	0.2	10
32	Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC). Expert Review of Anticancer Therapy, 2019, 19, 431-435.	1.1	10
33	Molecular and clonal evolution in recurrent metastatic gliosarcoma. Journal of Physical Education and Sports Management, 2020, 6, a004671.	0.5	10
34	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). JTO Clinical and Research Reports, 2022, 3, 100261.	0.6	9
35	<i>Candida glabrata</i> vertebral osteomyelitis in an immunosuppressed patient. International Journal of Rheumatic Diseases, 2014, 17, 229-231.	0.9	8
36	Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).. Journal of Clinical Oncology, 2018, 36, 9517-9517.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 780379.	1.3	7
38	An ethnopharmacological approach to the preliminary screening of native Australian herbal medicines for anticancer activity. <i>Journal of Complementary and Integrative Medicine</i> , 2015, 12, 245-9.	0.4	4
39	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience. <i>JCO Precision Oncology</i> , 2021, 5, 859-875.	1.5	4
40	Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. <i>Clinical Cancer Research</i> , 2022, 28, 13-22.	3.2	4
41	The role of immunotherapy in fusion-driven lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 461-464.	1.1	3
42	Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 11-20.	1.3	2
43	Comparative efficacy of treatments for brain metastases from non-small-cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis. <i>World Neurosurgery</i> , 2021, 158, e87-e87.	0.7	2
44	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354.	3.4	2
45	The Role of Liquid Biopsy in the Diagnostic Testing Algorithm for Advanced Lung Cancer. <i>Onco</i> , 2022, 2, 181-185.	0.2	2
46	Improving Precision and Implementation of Immuno-Oncology Biomarkers. <i>Journal of Thoracic Oncology</i> , 2021, 16, e91-e93.	0.5	0
47	Characteristics and outcomes of oncology patients requiring admission to an Australian intensive care unit.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21653-e21653.	0.8	0
48	Tumor-Agnostic Biomarkers: Heed Caution, and Why Cell of Origin Still Matters. <i>Onco</i> , 2021, 1, 95-100.	0.2	0
49	Trials without borders — decentralized trials and ensuring access to novel cancer therapies during a global pandemic. <i>ESMO Open</i> , 2022, , 100537.	2.0	0